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Abstract
Obstructıve sleep apnea syndrome is a clinical syndrome characterized by recurrent partial or total obstruction
of the upper respiratory tract. The main symptoms are snoring, excessive daytime sleepiness and witnessed
apnea. It is a disease that affects 3% to 7% of the middle-aged population. Studies and meta-analyzes have
shown that cardiovascular diseases are more common in patients with obstructıve sleep apnea syndrome.
Comorbid conditions such as obesity, metabolic syndrome and smoking are higher in obstructıve sleep apnea
syndrome patients than in the general population. In addition, hypoxia-reperfusion injury due to intermittent
oxygen desaturation occurring in obstructıve sleep apnea syndrome patients, endothelial dysfunction, increased
sympathetic system activity, platelet activation, monocyte increase, which play the main role in arteriosclerosis,
decreased and increased low-density lipoprotein cholesterol may also be the reason for the frequent occurrence
of cardiovascular diseases. The development of cardiovascular disease in obstructıve sleep apnea syndrome
patients is an important cause of morbidity and mortality. Evaluating white blood cell neutrophil/lymphocyte
ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, hematocrit, platelet distribution width, red cell
distribution width, C-reactive protein, and monocyte/high-density lipoprotein cholesterol ratio in the follow-up
of obstructıve sleep apnea syndrome patients may be helpful in predicting the development of cardiovascular
diseases. Whether obstructıve sleep apnea syndrome patients have metabolic syndrome or smoking should be
questioned. Obstructıve sleep apnea syndrome, obesity, smoking and depression are increasingly prevalent
diseases worldwide, leading to significant mortality and morbidity. Therefore, multicentre studies involving
different societies are needed.
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Obstructive sleep apnea syndrome (OSAS) is
a disease affecting 3% to 7% of the middle aged
population. OSAS is a clinical clinical syndrome
with partial or total obstruction of the recurrent up-
per respiratory tract. The main symptoms are snor-
ing, excessive daytime sleepiness and witnessed
apnea. The gold standard for diagnosis of OSAS is
overnight polysomnography (PSG). Diagnostic cri-
teria for OSAS are the variety of symptoms. In case
of PSG, the apnea hypopnea index (AHI)
is > 5 or the AHI is > 15 for an asymptomatic
patient [1, 2]. Recurrent nocturnal apnea episodes
in OSAS patients cause sympathetic system acti-
vation, increased oxidative stress, endothelial dys-
function, sudden increase in systemic hypertension,
hypoxia and hypercapnia [3]. Intermittent hypoxia
episodes with intermittent hypoxia episodes, which
are dormant, intermittent episodes of nocturnal hy-
poxemia induce the formation of oxygen radicals,
which leads to low-grade inflammation [4]. Inflam-
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mation is one of the main factors found in the onset
and progression of atherosclerosis [5]. There is a
critical aspect of inflammation in the etiopathogen-
esis of OSAS. Intermittent hypoxia initiates inflam-
mation. Inflammation also activates proaclamatory
cytokines and adhesion molecules in OSAS. Oxi-
dizing radicals and proteolytic enzymes accumulate
leukocytes and platelets on the blood vessel walls,
leading to endothelial dysfunction [6]. In structured
studies, autonomic and neurohumoral abnormalities
of OSAS continue during daytime; this has caused
the general circadian blood pressure rhythm to dete-
riorate and increase the variability of short and long
term blood pressure [7], where absolute blood pres-
sure, blood pressure fluctuations are in progress and
development of organ damage in preparing arterial
remodilling, microvascular damage, hemodynamic
imbalance, and vascular reactivity disorder. For
these reasons, cardiovascular diseases (CVD) are
more common in OSAS patients [8, 9].
There is endothelial dysfunction in the patho-
physiology of hypertension, diabetes, coronary artery
disease (CAD) and congestive heart failure. It is
also seen in terms of endothelial dysfunction in
OSAS patients. OSAS was found to be an inde-
pendent risk factor for CVD. There is also much
evidence that the incidence of cerebrovascular dis-
eases increases in OSAS patients [10, 11].
Chronic systemic inflammation of OSAS may
play an important role in the progression of CVD.
The final and neutrophil/lymphocyte ratio (NLR)
of whithe blood cells (WBC) is a good indicator of
inflammation [12]. Neutrophils mediate the innate
immune response that secretes mediators, and lym-
phocytes mediate the adaptive immune response
in the inflammation mechanism [13]. In addition,
OSAS has been reported to activate the platelet,
which is also related to inflammation, and to collect
it at the site of inflammation. Mean platelet vol-
ume (MPV) and platelet distribution width (PDW)
are indicators of platelet activity and are present
there with low oxygen saturation [14]. It reveals
platelet/lymphocyte ratio (PLR) as a new informa-
tive marker for extremely accurate prediction of
CVD [15]. Hematocrit (HTC) elevated in OSAS pa-
tients [16] as a result of secondary erythrocytosis in
hypoxemic conditions. There were hypoxia in struc-
tured studies when activation of the hypothalamus-
pituitary-adrenal axis erythropoiesis increased the
production of systemic cortisol levels and led to an
increase in HTC. In addition, red cell distribution
width (RDW) OSAS, which evaluates erythrocyte
variability, has an increased rate of inflammation.
As a result of structured studies of WBC, lympho-
cyte (LYM), NLR, MPV, PDW, PLR, RDW and
HTC etc., there is a negative correlation between
lymphocyte ratios and severity of OSAS and hypox-
emic status of low lymphocyte count. Svatikova et
al. showed that NLR and atrial natriuretic peptide
(ANP) are increased by hypoxia and sympathetic ac-
tivation. ANP may be an indicator that is expected
to reduce CVD risk with continuous positive airway
pressure (CPAP) treatment [17, 18, 19].
C-reactive protein (CRP), final PLR and NLR
are used as inflammatory markers and indepen-
dent risk factors for atherosclerosis [20]. History
of monocyte activation plays an important role in
the development of CVD such as heart failure and
atherosclerosis by causing chronic inflammation.
There is an important formation of inflammation in
CAD formation; increased inflammation in CAD
such as monocytes, lymphocytes, eosinophils and
neutrophils. Prentice et al. showed that patients
with CAD had higher monocyte, neutrophil and
eosinophil counts than those without CAD, and as-
sociated these findings with a high risk of CAD [21,
22]. The increase in neutrophils due to inflamma-
tion causes secretion of various cytokine types, pro-
teolytic enzymes.
Monocytes account for about one-fifth of periph-
eral blood cells. Macrophages and monocytes are
the most important cell types that cause the secre-
tion of proinflammatory and prooxidant cytokines
in the inflammation region. Monocytes are cells
that have a significant effect on the development
of atherosclerotic lesions [23]. Monocytes are re-
sponsible for vascular endothelial damage in the
pathogenesis of atherosclerosis. Monocytes phago-
cytose lipids to become macrophages and secrete
metalloproteinases such as elastase and collagenase,
which cause atherosclerosis. The role of monocytes
in atherogenesis is not limited to macrophage func-
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tion within the arterial wall, and also has effects
on immune stimulating agents, growth factors, cy-
tokines, oxidized lipids, platelet-derived activation
products. For these reasons, circulating monocytes
and macrophages contribute to the pathogenesis and
complications of CVD [24].
In the CANTOS (Canakinumab Anti-Inflammatory
Thrombosis Outcome Study), it was shown that
monoclonal antibodies specifically targeting inter-
leukin - β would reduce cardiovascular events with-
out affecting plasma low-density lipoprotein (LDL)
or lipoproteins [25].
Lymphocyte count decreases in response to in-
flammation conditions and is associated with poor
prognosis in coronary artery disease. Lymphocyte/
monocyte ratio (LMR) has been proposed as a marker
for different inflammation and also has prognostic
and predictive value. In a study of patients with
acute pulmonary embolism, low LMR was found
to be an independent variable for in-hospital and
short-term mortality. In another study, a significant
negative correlation was found between coronary
slow flow and LMR [26, 27].
In a recent study, Tamaki et al. showed that
the number of monocytes in OSAS patients was
higher than in the control group. Monocyte count
was positively correlated with the severity of OSAS
and it was emphasized that it could be used as a
marker for predicting OSAS severity [28].
The association of atherosclerosis and an abnor-
mal lipid profile is common in CAD. Triglyceride,
total cholesterol and LDL levels increase with the
severity of OSAS, while high-density lipoprotein
(HDL) levels decrease. High LDL and low HDL
concentrations are strong risk factors for CAD [29,
30].
The relationship between OSAS and dyslipi-
demia is due to the formation of stearoyl-coenzyme
A desaturase-1 and reactive oxygen species, per-
oxidation of lipids and activation of the sympa-
thetic system as a result of chronic intermittent
hypoxia [31].
Low HDL cholesterol and high monocyte count
seem to be indirect indicators of inflammation. HDL
cholesterol consists of heterogeneous particles that
can be classified by size, density, charge, shape,
lipid and protein composition. In addition to choles-
terol transport from HD blood vessels to tissues,
their functions including antioxidant, anti-inflammatory,
antiapoptotic, antithrombotic and antiatheroscle-
rotic effects result from these heterogeneous par-
ticles [32, 33]. Small HDL cholesterol was found
to be associated with the presence and severity of
atherosclerotic disease; on the contrary, large HDL
cholesterol showed a negative correlation with the
presence of CAD and the severity and progression
of the disease [34]. HDL cholesterol has been
shown to protect endothelial cells against the neg-
ative effects of LDL cholesterol and to prevent
oxidation of LDL molecules. For these reasons,
HDL cholesterol has been thought to have both
anti-inflammatory and antioxidant effects [35, 36].
HDL cholesterol molecules prevent the migration
of macrophages and allow oxidized cholesterol to
flow through these cells. Recent studies also re-
vealed that HDL has effects on monocyte activation
and control of adhesion [37, 38]. In addition to
anti-inflammatory and antioxidant effects of HDL
molecules, vasorelaxan and endothelial nitric oxide
synthase has the effect of increasing expression [39].
Monocytes show proinflammatory and prooxidant
effects; however, HDL cholesterol may have a pre-
ventive effect on this process. In a study, it was
stated that CPAP treatment in OSAS patients may
have positive effects on dyslipidemia, atherosclero-
sis and CVD [40].
Monocyte/HDL cholesterol ratio (MHR) can
be practical, cost-effective and highly predictive of
CVD. The use of MHR as a marker has an eco-
nomic advantage. It is less expensive as compared
to other inflammatory markers such as interleukin-1
(IL-1), interleukin-6 (IL-6) tumor necrosis factor-
α , monocyte chemoattractant protein-1, and serum
amyloid A. MHR has a positive correlation with
CRP in determining CVD risk. In addition to being
a marker of systemic inflammation, MHR may be
useful in predicting clinical outcomes in CVD as-
sociated with atherosclerotic development, progres-
sion, and inflammatory conditions [41, 42]. Stud-
ies have suggested that MHR is associated with
systemic inflammation and endothelial dysfunction
and may be accepted as a prognostic marker in
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CVD [43, 44].
Laboratory studies revealed that HDL choles-
terol levels were higher in women and MHR levels
were lower in men. These findings may help ex-
plain why men are more likely to develop vascular
endothelial dysfunction and atherosclerosis than
women [45].
MHR is strongly associated with the severity of
CVD and OSAS and can be used as a biomarker
to predict CVD in patients with OSAS [36]. In
a study, it was found that MHR values increased
with increasing severity of OSAS [46]. In addi-
tion, it has been shown that MHRs are significantly
higher in OSAS patients with CVD as compared
to non-CVD patients and that MHR can be used
as an independent predictor of CVD in OSAS pa-
tients. In addition, previous studies showed a sig-
nificantly higher number of monocytes in patients
with OSAS as compared to the control group. In
the severe OSAS group, the number of monocytes
was found to be higher than those with moderate
and mild OSAS. These findings may explain the
higher incidence of cardiovascular events in severe
OSAS. There was a positive correlation between
MHR and the severity of hypoxemia defined by
oxygen desaturation index (ODI) [47]. MHR, AHI,
rapid eye movement (REM) -AHI, non-REM-AHI
and oxygen saturation have been shown to increase
significantly as time increases below 90% and the
minimum oxygen concentration decreases [2] in-
dependently associated with corner atherosclerosis
assessed by SYNTAX (Synergy Between Percuta-
neous Coronary Intervention With Taxus and Car-
diac Surgery) score in patients with independent
coronary artery disease. In addition, a positive cor-
relation was found between CRP and MHR [48].
Recently, it has been shown that MHR is an in-
dependent variable in terms of 5-year mortality in
cardiovascular events, hospitalization and ST seg-
ment elevation myocardial infarction (STEMI) [49].
All these findings show the importance of MHR in
inflammation, which plays an important role in the
development of cardiovascular events.
It has been shown that MHR is higher in patients
with primary hypertension (PHT) than controls. In
addition, in PHT group, patients with asymptomatic
organ damage (AOH) had higher MHR than patients
without AOH. When the newly diagnosed untreated
hypertensive patients and healthy group were com-
pared, MHR values were found to be higher than in
the control group [50].
Higher MHR values have been found in patients
with acute ischemic stroke (AIS) as compared to
controls. High MHR levels in patients with AIS
were found to be a significant independent variable
of 30-day mortality [51].
In a study, it was shown that 24.3% of men
and 50% of women among OSAS patients had
metabolic syndrome (MS) [52]. The components
of MS such as impaired glucose tolerance, central
obesity, hypertension and dyslipidemia were clearly
associated with CVD [53, 54]. In recent years, adi-
pose tissue has been shown to be an endocrinolog-
ically and metabolically active organ. Adipokines
are a group of specific signal molecules involved
in many processes such as saturation, energy bal-
ance, inflammation, insulin resistance/sensitivity,
angiogenesis, lipid metabolism and atherosclero-
sis [55, 56]. Subclinical chronic inflammation is a
part of the insulin resistance syndrome, and chronic
inflammation has been shown to have an indepen-
dent association with insulin resistance. Atheroscle-
rosis, which is one of the mortal complications of
MS, is considered an inflammatory disease [57].
The activation of MS monocytes is associated with
inflammation and atherosclerosis. In a study, the
mean LMR was significantly lower and the CRP
value was significantly higher in patients with MS
as compared to patients without MS. In addition, the
mean MHR value in patients with MS was reported
to be significantly higher [58].
The prevalence of smoking in OSAS patients
is higher than in non-OSAS patients. In addition,
male OSAS patients seem to smoke more than
women [59]. Smoking is known to be an important
risk factor for metabolic disorders such as OSAS.
Various compounds in cigarette smoke, such as
volatile organic compounds, heavy metals and nico-
tine, increase oxidative stress and systemic inflam-
mation, which play a role in the emergence of
metabolic disorders [60]. Smoking is associated
with high MHR levels and may be a useful indica-
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tor of a systemic inflammatory response in smok-
ers. Smokers with a high MHR level can be eas-
ily identified during routine complete blood count
(CBC) analysis and possibly benefit from preven-
tive treatment. Increased serum WBC, monocytes
and MHR levels may be associated with inflamma-
tion in the pathophysiology of smoking. In addi-
tion, high hemoglobin and HTC values observed in
smokers and dyslipidemia may be related to smok-
ing. The relationship between smoking, systemic in-
flammatory response, vascular endothelial damage
and atherosclerosis has been well defined both in
the past and more recently [61, 62]. MHR is a sim-
ple, easy and cost-effective tool that should be used
to predict the systemic inflammatory response and
possible endothelial dysfunction in smokers [45].
Conclusions
OSAS is a clinical syndrome characterized by recur-
rent partial or total obstruction of the upper respira-
tory tract. Studies and meta-analyzes have shown
that CVD are more common in patients with OSAS.
The development of CVD in OSAS patients is an
important cause of morbidity and mortality. In the
follow-up of OSAS patients, WBC, NLR, PLR,
LMR, HTC, PDW, RDW CRP, and MHR tests may
be helpful in predicting CVD of patients. In addi-
tion, whether OSAS patients have metabolic syn-
drome or smoking should be questioned. OSAS,
obesity, smoking and depression are increasingly
prevalent diseases worldwide, leading to significant
mortality and morbidity. Therefore, multicentre
studies involving different societies are needed.
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